Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload ...

4 September 2026 · By · Wire by Fusion42

Published

4 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 4 September 2026 · Fusion42 review

Acepodia has received FDA clearance to proceed with an Investigational New Drug (IND) application for ACE723, a novel dual-payload antibody-drug conjugate intended for cancer treatment.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You now have a regulatory pathway open for ACE723 in the US after FDA IND clearance, signalling faster route to clinical trials. Move quickly to secure trial sites and partners to capitalise on this early clinical momentum.

◆ Coverage

1 source · 4 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-clearanceind-applicationantibody-drug-conjugateoncologydual-payload